<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069012</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000688</org_study_id>
    <nct_id>NCT05069012</nct_id>
  </id_info>
  <brief_title>Intrathecal Morphine for Cesarean Delivery</brief_title>
  <official_title>Optimal Dose of Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blinded non-inferiority study comparing the duration of pain&#xD;
      relief when patients receive one of three doses of spinal morphine. Enrolled patients will be&#xD;
      randomly assigned to receive either 50 mcg, 150 mcg, or 250 mcg. All patients will receive&#xD;
      standardized postoperative care, including multimodal analgesia. The primary outcome will be&#xD;
      the time until the patient requests additional opioid pain medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, double-blind, controlled trial, with a non-inferiority design.&#xD;
      Patients will be randomly assigned to receive either intrathecal morphine 50 mcg, 150 mcg, or&#xD;
      250 mcg based on a pre-assigned randomization sequence. This medication will be administered&#xD;
      as part of their spinal anesthesia for cesarean delivery. the patient, clinician who&#xD;
      administers the spinal anesthesia, and investigator who follows the patient will all be&#xD;
      blinded to the dose of medication.&#xD;
&#xD;
      All patients will receive standard of care for cesarean delivery and routine nursing care.&#xD;
      This includes: preoperative intravenous catheter placement with preoperative IV fluid,&#xD;
      standard American Society of Anesthesiologists monitoring, and neuraxial anesthesia placement&#xD;
      (either spinal or combined spinal epidural) in sterile fashion. Each patient will receive&#xD;
      standard cesarean induction dose of intrathecal medication consisting of 1.5ml of 0.75%&#xD;
      hyperbaric bupivacaine, fentanyl 25 mcg. At end of surgery, all patients will receive&#xD;
      standard dose of ketorolac 30 mg IV and acetaminophen 1 gm IV and continue with redosing&#xD;
      every 6 and 8 hours (respectively) for 24 hours. On arrival to PACU, all patients will&#xD;
      receive standard nursing care with standard monitoring of side effects. On discharge from&#xD;
      PACU, patients will be transferred to postpartum floor and receive standard nursing care and&#xD;
      monitoring.&#xD;
&#xD;
      Over the following 24 hours, the patient will receive all standard post-cesarean care. For&#xD;
      treatment of breakthrough pain, medications will provided be per standard care: oxycodone&#xD;
      5-10 mg PO every four hours PRN for pain. If the patient is not comfortable after receiving&#xD;
      oral oxycodone they will be assessed by an anesthesia provider for either regional nerve&#xD;
      block or additional opioids, as a one-time dose or by patient controlled analgesia (PCA).&#xD;
&#xD;
      For treatment for side effects, medications will provided be per standard care: ondansetron&#xD;
      4mg IV as first-line for nausea/vomiting, promethazine 6.25 mg IV or Haloperidol 0.5-1mg IV&#xD;
      for refractory nausea/vomiting. Naloxone 0.04 mg IV for refractory pruritus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization maintained in the research pharmacy. Blinded syringe delivered to the investigator for the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of pain relief</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to patient request for first dose of oral rescue pain medicine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual analogue pain scores reported by the patient. Scale measured on a line from 0 to 100 mm, with 0 representing 'no pain' and 100 representing 'worst possible pain'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery</measure>
    <time_frame>24 hours</time_frame>
    <description>Quality of Recovery Score following Cesarean Delivery Questionnaire (ObsQoR-11). This is a multi-dimensional wellness scale ranging from 0 (worst) to 10 (best) along 12 axis items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of nausea and vomiting requiring treatment with a medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of pruritus requiring treatment with a medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>50 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief</description>
    <arm_group_label>150 micrograms</arm_group_label>
    <arm_group_label>250 micrograms</arm_group_label>
    <arm_group_label>50 micrograms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women (ASA 2)&#xD;
&#xD;
          -  Between 18 and 45 years old&#xD;
&#xD;
          -  Singleton term pregnancies&#xD;
&#xD;
          -  Planned neuraxial anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Known allergy or contraindication to any medication used in the study&#xD;
&#xD;
          -  Significant medical or obstetrical disease (ASA â‰¥ 3)&#xD;
&#xD;
          -  Opioid use disorder&#xD;
&#xD;
          -  Chronic pain syndrome&#xD;
&#xD;
          -  Daily or near daily opioid use within last 3 weeks.&#xD;
&#xD;
          -  Patient receiving a Monoamine oxidase inhibitors (MOAi)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philip Hess</last_name>
    <phone>6172832126</phone>
    <email>phess@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Phillip Hess</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cesarean</keyword>
  <keyword>morphine</keyword>
  <keyword>multimodal analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

